Kenvue Inc.
$ 17.38
0.70%
14 Apr - close price
- Market Cap 33,368,144,000 USD
- Current Price $ 17.38
- High / Low $ 17.44 / 17.13
- Stock P/E 22.87
- Book Value 5.62
- EPS 0.76
- Next Earning Report 2026-05-14
- Dividend Per Share $0.82
- Dividend Yield 4.78 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.14 %
- 52 Week High 24.13
- 52 Week Low 13.69
About
Kenvue Inc. is a consumer health company globally.
Analyst Target Price
$19.75
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-17 | 2025-11-03 | 2025-08-07 | 2025-05-08 | 2025-02-06 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-02-08 | 2023-10-26 | 2023-07-20 | 2023-06-02 |
| Reported EPS | 0.17 | 0.28 | 0.29 | 0.24 | 0.26 | 0.28 | 0.32 | 0.28 | 0.31 | 0.31 | 0.32 | 0.19 |
| Estimated EPS | 0.15 | 0.26 | 0.28 | 0.23 | 0.26 | 0.27 | 0.28 | 0.25 | 0.28 | 0.31 | 0.3 | 0.32 |
| Surprise | 0.02 | 0.02 | 0.01 | 0.01 | 0 | 0.01 | 0.04 | 0.03 | 0.03 | 0 | 0.02 | -0.13 |
| Surprise Percentage | 13.3333% | 7.6923% | 3.5714% | 4.3478% | 0% | 3.7037% | 14.2857% | 12% | 10.7143% | 0% | 6.6667% | -40.625% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.27 |
| Currency | USD |
Previous Dividend Records
| Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-02-25 | 2025-11-26 | 2025-08-27 | 2025-05-28 | 2025-02-26 | 2024-11-27 | 2024-08-28 | 2024-05-22 | 2024-02-28 | 2023-11-22 |
| Amount | $0.2075 | $0.2075 | $0.2075 | $0.205 | $0.205 | $0.205 | $0.205 | $0.2 | $0.2 | $0.2 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KVUE
2026-04-15 13:08:03
Kenvue Inc. has appointed Heather Howlett as interim Chief Financial Officer and Chief Accounting Officer, effective May 12, 2026, following the departure of Amit Banati. Ms. Howlett, previously Kenvue’s Chief Accounting Officer since May 2023, will receive a monthly stipend of $125,000 in addition to her current compensation. This transition occurs amidst recent financial reports where Kenvue's Q4 earnings missed analyst expectations.
2026-04-15 13:06:55
Kenvue (NYSE: KVUE) announced a leadership change in its finance department, with current CFO Amit Banati stepping down on May 12, 2026. Heather Howlett, currently Chief Accounting Officer, will assume the roles of interim Chief Financial Officer and Chief Accounting Officer. Howlett will receive a monthly stipend of $125,000 in addition to her existing compensation package, which includes a base salary of $544,116, a target bonus of $299,264, and an annual equity award of $420,000 for fiscal year 2026.
2026-04-15 12:55:05
Kimberly-Clark Corporation announced its post-closing organizational structure and key leadership team in anticipation of completing its acquisition of Kenvue Inc. The new structure will feature four business segments: North America, Asia Pacific Focus Markets, EMEA, and Enterprise Markets. Mike Hsu will continue as Chairman and CEO, leading a team designed for agility and speed to capitalize on growth opportunities in the health and wellness sector.
2026-04-14 22:28:52
Barclays has maintained an "Equal-Weight" rating for Kenvue (KVUE) but lowered its price target from $19.00 to $18.00. Despite this cautious outlook, Kenvue is considered undervalued with a GF Value™ of $20.54 against a current price of $17.38 and a moderate GF Score™ of 58/100. The company, a consumer health spin-off from Johnson & Johnson, boasts strong valuation but shows areas for improvement in financial strength and growth.
2026-04-14 20:24:01
The article highlights Listerine Cool Mint as a key stable product for Kenvue Inc. in a volatile consumer market. It emphasizes the product's essential role in daily oral hygiene and its resilience against economic challenges, providing consistent revenue for Kenvue due to strong market share and consumer loyalty. The piece also discusses Kenvue's strategy centered on proven self-care brands like Listerine and the market drivers fueling steady growth in oral care.
2026-04-14 18:08:53
Johnson & Johnson (JNJ) reported a strong first quarter in 2026, driven by growth in key medicines like Darzalex and Tremfya, validating its selection as a new Club stock. Despite the impact of Stelara losing patent protection, J&J delivered solid results and raised its full-year guidance, with management maintaining a "line of sight" to double-digit revenue growth by the end of the decade. The company is introducing new products like the daily psoriasis pill Icotyde, which has significant sales potential, and plans to provide more details on its growth targets at a business review meeting in December.
